This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
“Intellia Therapeutics has surged 41% year-to-date amid FDA clearance to resume a key Phase 3 trial for its CRISPR-based therapy targeting hereditary ATTR amyloidosis with polyneuropathy, positioning the company as a frontrunner in gene editing innovation. However, ongoing clinical risks, high cash burn rates, and competition from established treatments raise questions about its long-term viability … Read more